FDA’s Top Biologics Regulator Vinay Prasad Steps Down Amid Rare Disease Drug Approval Row

Vinay Prasad, chief medical and scientific officer of the US Food and Drug Administration and director of its Center for Biologics Evaluation and Research, is departing his position at the end of April 2026. FDA Commissioner Marty Makary confirmed the departure, describing Prasad’s tenure as productive despite the turbulent circumstances surrounding his exit.

The announcement comes amid escalating disputes between the FDA and pharmaceutical companies over the approval of therapies for rare diseases. Most notably, the agency has faced criticism over its handling of a Huntington’s disease gene therapy developed by Dutch biotechnology company uniQure, with allegations that the FDA reversed previous agreements on clinical trial design requirements.

Prasad’s departure marks the second time he has left the FDA. In July 2025, just three months after taking the role, he resigned following public controversy surrounding the agency’s approach to a gene therapy for Duchenne muscular dystrophy manufactured by Sarepta Therapeutics. That decision had drawn opposition from rare disease patient advocacy groups, who escalated their concerns to political leadership. However, he was reinstated two weeks later following intervention from FDA leadership.

During his tenure, Prasad oversaw some of the FDA’s most significant regulatory initiatives. These included implementing a requirement that pharmaceutical companies provide two pivotal clinical trials instead of multiple trials to support drug approval, establishing a national priority review programme, and developing a framework for approving therapies for ultra-rare diseases through single-arm trials supported by external data. Makary highlighted these achievements as evidence of Prasad’s substantial contributions to modernising the agency’s approach.

However, Prasad’s leadership of the Center for Biologics Evaluation and Research has coincided with increased scrutiny of rare disease treatments. According to regulatory analysts, at least five cell and gene therapies have been rejected by the centre under Prasad’s direction—treatments that industry observers and some medical experts suggest might have received approval under previous FDA leadership. These rejections have sparked concerns among rare disease patient advocates about inconsistency between the FDA’s stated commitment to regulatory flexibility and its actual decision-making.

The most recent controversy involves uniQure’s Huntington’s disease treatment. The company has stated that the FDA previously agreed to a trial design based on external controls rather than traditional comparator groups. The FDA under Prasad’s leadership subsequently reversed this position, leading to public disagreements between the regulator and the biotech firm. The dispute attracted significant media attention and prompted criticism of the agency’s decision-making process.

Prasad’s time at the FDA has been marked by considerable internal and external scrutiny. Multiple agency staff reported concerns about his management approach, describing a workplace environment characterised by increased scrutiny of decision-making processes and limited autonomy for career staff. Eight FDA officials told journalists in October 2025 that Prasad had created an atmosphere of mistrust, whilst several employees filed formal complaints about his management style with the agency’s human resources department.

During his second tenure, Prasad made significant personnel changes at CBER, removing at least seven leaders from their positions. In one notable instance, he reassigned the individual responsible for vaccine safety and surveillance, taking on those responsibilities himself. This degree of centralised control was described as unusual by former FDA officials and agency staff.

Prasad’s departure occurs during a period of significant change at the FDA more broadly. The agency has experienced several high-profile departures, including Richard Padzur, a veteran oncology regulator who left as head of the Center for Drug Evaluation and Research after less than a month in the position. Tracy Beth Høeg, his successor, became the fifth person to lead that centre in 2025.

Under the current FDA leadership and health secretary Robert F Kennedy Jr, the agency has adopted a more cautious approach to certain regulatory areas. Prasad himself drew criticism for refusing to review Moderna’s application for a new messenger RNA influenza vaccine—a decision reversed only after intervention from the White House.

Makary stated that the FDA would identify Prasad’s successor before his departure at the end of April. Industry analysts suggest that his exit may create opportunities for more flexible approval pathways for rare disease therapies, though uncertainty remains about whether recent regulatory initiatives will continue under new leadership.

Key Takeaways

• Dr Vinay Prasad is stepping down as head of the FDA’s Center for Biologics Evaluation and Research at the end of April 2026, marking his second departure from the agency
• His exit follows disputes with pharmaceutical companies, particularly regarding approval decisions for rare disease treatments including Huntington’s disease gene therapy
• Under Prasad’s leadership, several cell and gene therapies were rejected by the agency, creating concerns amongst rare disease advocates about regulatory consistency
• The FDA has committed to naming a successor before his departure

What This Means for Kent Residents

Whilst the FDA’s decisions are made in America, they have implications for UK patients with rare diseases who may seek access to treatments through private channels or future approvals. Patients in Kent with rare genetic conditions should continue to consult their NHS specialists about approved treatment options. For those seeking access to experimental therapies not yet available in the UK, the NHS Specialised Commissioning team and rare disease centres at Kent and Medway NHS Trust can provide guidance on legitimate pathways and clinical trials. The regulatory changes at the American FDA may eventually influence how the UK Medicines and Healthcare Products Regulatory Agency evaluates similar therapies, so monitoring these developments remains important for patients and clinicians managing rare diseases in the region.